JP2024513907A5 - - Google Patents

Info

Publication number
JP2024513907A5
JP2024513907A5 JP2023561616A JP2023561616A JP2024513907A5 JP 2024513907 A5 JP2024513907 A5 JP 2024513907A5 JP 2023561616 A JP2023561616 A JP 2023561616A JP 2023561616 A JP2023561616 A JP 2023561616A JP 2024513907 A5 JP2024513907 A5 JP 2024513907A5
Authority
JP
Japan
Prior art keywords
seq
msec
enhancer
miniaturized
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513907A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023915 external-priority patent/WO2022216988A2/en
Publication of JP2024513907A publication Critical patent/JP2024513907A/ja
Publication of JP2024513907A5 publication Critical patent/JP2024513907A5/ja
Pending legal-status Critical Current

Links

JP2023561616A 2021-04-09 2022-04-07 筋特異的遺伝子発現用の人工調節カセット Pending JP2024513907A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163173295P 2021-04-09 2021-04-09
US63/173,295 2021-04-09
PCT/US2022/023915 WO2022216988A2 (en) 2021-04-09 2022-04-07 Artificial regulatory cassettes for muscle-specific gene expression

Publications (2)

Publication Number Publication Date
JP2024513907A JP2024513907A (ja) 2024-03-27
JP2024513907A5 true JP2024513907A5 (cg-RX-API-DMAC7.html) 2025-04-15

Family

ID=83546588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561616A Pending JP2024513907A (ja) 2021-04-09 2022-04-07 筋特異的遺伝子発現用の人工調節カセット

Country Status (4)

Country Link
US (1) US20240200093A1 (cg-RX-API-DMAC7.html)
EP (2) EP4707401A3 (cg-RX-API-DMAC7.html)
JP (1) JP2024513907A (cg-RX-API-DMAC7.html)
WO (1) WO2022216988A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121311497A (zh) 2023-04-14 2026-01-09 精密生物科学公司 肌肉特异性表达盒
WO2024216116A1 (en) * 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
WO2025015036A1 (en) * 2023-07-10 2025-01-16 Kate Therapeutics, Inc. Aav gene therapy approach for treating lgmd2b/dysferlinopathy
WO2025129079A1 (en) * 2023-12-13 2025-06-19 Tenaya Therapeutics, Inc. Cardiac-specific promoters for gene therapy
WO2026060294A1 (en) * 2024-09-13 2026-03-19 The Regents Of The University Of California Methods and compositions for treating skeletal muscle disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183984B1 (en) * 1991-11-12 2001-02-06 Arch Development Corporation Sequences for promoting epidermal cell-specific transcription
US6967019B2 (en) * 1999-04-06 2005-11-22 The Regents Of The University Of California Production of pancreatic islet cells and delivery of insulin
EP1303617B1 (en) * 2000-07-14 2007-09-12 The Regents Of The University Of Michigan Mutant muscle-specific enhancers
WO2002072024A2 (en) * 2001-03-12 2002-09-19 Progenetics Llc Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto
US10196636B2 (en) * 2011-04-21 2019-02-05 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
US20130136729A1 (en) * 2011-11-11 2013-05-30 University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors
WO2013102904A1 (en) * 2012-01-05 2013-07-11 Hadasit Medical Research Services & Development Ltd. Methods and compositions for gene delivery
WO2016115543A2 (en) * 2015-01-16 2016-07-21 University Of Washington Novel micro-dystrophins and related methods of use
EP3405579A1 (en) * 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2020142714A1 (en) * 2019-01-04 2020-07-09 Exonics Therapeutics, Inc. Aav expression cassette and aav vectors comprising the same
KR20210148273A (ko) * 2019-04-08 2021-12-07 제네똥 근육 발현을 위한 하이브리드 프로모터
JP7565620B2 (ja) * 2019-05-28 2024-10-11 株式会社モダリス Dmpk遺伝子を標的とした筋ジストロフィーの治療方法
EP4004214A1 (en) * 2019-07-26 2022-06-01 RegenxBio Inc. Engineered nucleic acid regulatory element and methods of uses thereof
WO2021050666A1 (en) * 2019-09-11 2021-03-18 Aav Gene Therapeutics, Inc. Aav-zyme and use for infusion replacement therapy

Similar Documents

Publication Publication Date Title
JP7860169B2 (ja) 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
JP2022500066A5 (cg-RX-API-DMAC7.html)
US10413598B2 (en) Factor IX gene therapy
JP2026027271A5 (cg-RX-API-DMAC7.html)
AU2010311376B2 (en) Cardiac-specific nucleic acid regulatory elements and methods and use thereof
JP2021519791A5 (cg-RX-API-DMAC7.html)
JP2023524291A5 (cg-RX-API-DMAC7.html)
CN112040988A (zh) 修饰的aav衣壳多肽用于治疗肌肉疾病
JP2024545183A5 (cg-RX-API-DMAC7.html)
JP2022530824A5 (cg-RX-API-DMAC7.html)
JP2024041821A5 (cg-RX-API-DMAC7.html)
JP2025515979A5 (cg-RX-API-DMAC7.html)
ES2297830T3 (es) Control de la expresion del gen del igf-i.
JP2022066336A5 (cg-RX-API-DMAC7.html)
KR20230084542A (ko) 플라코필린 2 유전자 치료 방법 및 조성물
JP2024518817A5 (cg-RX-API-DMAC7.html)
JP2003503355A5 (cg-RX-API-DMAC7.html)
JP2023549357A5 (cg-RX-API-DMAC7.html)
JP2024545186A5 (cg-RX-API-DMAC7.html)
JP2021533801A5 (cg-RX-API-DMAC7.html)
JP2021525531A5 (cg-RX-API-DMAC7.html)
CN109010799B (zh) RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途
JP2021534796A5 (cg-RX-API-DMAC7.html)
CN112739818A (zh) 编码因子ix的核苷酸
CN111088268A (zh) 一种高尿酸血症的基因治疗药物